Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US16342892Application Date: 2017-10-17
-
Publication No.: US10676461B2Publication Date: 2020-06-09
- Inventor: Katsunori Nagai , Takuto Kojima , Shinichi Imamura , Masao Hirakata
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka-shi, Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka-shi, Osaka
- Agency: Casimir Jones, S.C.
- Agent Anne M. Reynolds
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5b53538a
- International Application: PCT/JP2017/037503 WO 20171017
- International Announcement: WO2018/074461 WO 20180426
- Main IPC: C07D401/14
- IPC: C07D401/14 ; A61P3/00 ; A61P35/00 ; A61K9/00 ; A61K31/05 ; A61K31/09 ; A61K31/57 ; A61K31/58 ; A61K31/6615 ; A61P43/00 ; A61K31/498 ; A61K45/06

Abstract:
The present invention relates to N-((3S,4R)-1-((8-chloroquinoxalin-6-yl)carbonyl)-3-(4-fluorophenyl)piperidin-4-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide, which is a compound that can be useful for the treatment or prevention of SPT-related diseases including congenital diseases associated with the storage of sphingolipids, such as cancer and Niemann-Pick disease, or a salt thereof.
Public/Granted literature
- US20190263784A1 HETEROCYCLIC COMPOUND Public/Granted day:2019-08-29
Information query